# Study of Amplitude-Modulated Radiofrequency Electromagnetic Fields in Metastatic Pancreatic Cancer

> **NCT05776524** · PHASE2 · RECRUITING · sponsor: **THERABIONIC INC.** · enrollment: 46 (estimated)

## Conditions studied

- Pancreatic Cancer
- Metastatic Adenocarcinoma

## Interventions

- **DRUG:** Nab paclitaxel
- **DRUG:** Gemcitabine
- **DEVICE:** TheraBionic

## Key facts

- **NCT ID:** NCT05776524
- **Lead sponsor:** THERABIONIC INC.
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-06-13
- **Primary completion:** 2027-07
- **Final completion:** 2029-07
- **Target enrollment:** 46 (ESTIMATED)
- **Last updated:** 2025-03-25

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05776524

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05776524, "Study of Amplitude-Modulated Radiofrequency Electromagnetic Fields in Metastatic Pancreatic Cancer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05776524. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*